Dona Alberti

3.4k total citations
90 papers, 2.8k citations indexed

About

Dona Alberti is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dona Alberti has authored 90 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 32 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dona Alberti's work include Cancer Treatment and Pharmacology (27 papers), Colorectal Cancer Treatments and Studies (12 papers) and Cancer therapeutics and mechanisms (12 papers). Dona Alberti is often cited by papers focused on Cancer Treatment and Pharmacology (27 papers), Colorectal Cancer Treatments and Studies (12 papers) and Cancer therapeutics and mechanisms (12 papers). Dona Alberti collaborates with scholars based in United States, Spain and Italy. Dona Alberti's co-authors include George Wilding, Rebecca Marnocha, Rhoda Arzoomanian, Howard H. Bailey, Kendra D. Tutsch, K D Tutsch, Chris Feierabend, R Z Arzoomanian, Marcia Pomplun and Jill Kolesar and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Dona Alberti

88 papers receiving 2.7k citations

Peers

Countries citing papers authored by Dona Alberti

Since Specialization

Citations

This map shows the geographic impact of Dona Alberti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dona Alberti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dona Alberti more than expected).

Fields of papers citing papers by Dona Alberti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dona Alberti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dona Alberti. The network helps show where Dona Alberti may publish in the future.

Co-authorship network of co-authors of Dona Alberti

This figure shows the co-authorship network connecting the top 25 collaborators of Dona Alberti. A scholar is included among the top collaborators of Dona Alberti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dona Alberti. Dona Alberti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Role of oophoropexy in pediatric primary ovarian torsion without adnexal lesions: A systematic review and meta-analysis 2026 ·Journal of Pediatric Surgery ·(unknown), (unknown), (unknown), Filippo Parolini, (unknown), Giovanni Boroni, Dona Alberti	0
2	A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies 2013 ·Investigational New Drugs ·William R. Schelman, Anne M. Traynor, Kyle D. Holen, Jill Kolesar, Steven Attia, Tien Hoang, Jens C. Eickhoff, Zhisheng Jiang, Dona Alberti, Rebecca Marnocha, Joel M. Reid, Matthew M. Ames, Renee M. McGovern, Igor Espinoza‐Delgado, James R. Wright, George Wilding, Howard H. Bailey	24
3	A Phase I Study of Capecitabine, Oxaliplatin, and Lapatinib in Metastatic or Advanced Solid Tumors 2011 ·Clinical Colorectal Cancer ·(unknown), Ronald A. Fleming, Carolyn J. Bowen, Mohammed M. Dar, Dona Alberti, (unknown), Noelle K. LoConte, (unknown), Kyle D. Holen	7
4	A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors 2009 ·Investigational New Drugs ·Anne M. Traynor, Michael S. Gordon, Dona Alberti, David S. Mendelson, (unknown), George Wilding, Richard E. Gammans, William L. Read	14
5	A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer 2008 ·Cancer Chemotherapy and Pharmacology ·Noelle K. LoConte, James P. Thomas, Dona Alberti, (unknown), (unknown), Rebecca Marnocha, (unknown), Peter Geiger, Jens C. Eickhoff, George Wilding, Jill Kolesar	16
6	Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with clinical stage D0 prostate cancer 2007 ·Cancer Research ·Edward J. Dunphy, Mary Jane Staab, Dorothea Horvath, Jane Straus, Dona Alberti, Glenn Liu, George Wilding, Douglas G. McNeel	1
7	Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine® 2007 ·Journal of Inorganic Biochemistry ·Jill Kolesar, William R. Schelman, Peter Geiger, Kyle D. Holen, Anne M. Traynor, Dona Alberti, James P. Thomas, Christopher R. Chitambar, George Wilding, William E. Antholine	29
8	A Phase I Study of a DNA Vaccine Targeting Prostatic Acid Phosphatase in Patients with Stage D0 Prostate Cancer 2005 ·Clinical Genitourinary Cancer ·(unknown), Mary Jane Staab, (unknown), Jane Straus, (unknown), (unknown), (unknown), Dona Alberti, Glenn Liu, George Wilding, Jens C. Eickhoff, Douglas G. McNeel	12
9	Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol 2002 ·Cancer Chemotherapy and Pharmacology ·James P. Thomas, Kendra D. Tutsch, James F. Cleary, Howard H. Bailey, Rhoda Arzoomanian, Dona Alberti, (unknown), Chris Feierabend, (unknown), Rebecca Marnocha, Amy Dresen, George Wilding	100
10	Phase I clinical and pharmacokinetic trial of irofulven 2001 ·Cancer Chemotherapy and Pharmacology ·James Thomas, Rhoda Arzoomanian, Dona Alberti, Chris Feierabend, (unknown), Kendra D. Tutsch, Thomas E. Steele, Rebecca Marnocha, Charlotte G. Smith, Sheri L. Smith, John R. MacDonald, George Wilding, Howard H. Bailey	16
11	A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors 1998 ·Investigational New Drugs ·Jordan Berlin, Dona Alberti, Rhoda Arzoomanian, Chris Feierabend, (unknown), Kim Binger, (unknown), George Wilding	33
12	Efficacy of a new formulation of desferrioxamine (CGH 749B) given as subcutaneous bolus injections in transfusion-dependent beta-thalassemic patients. 1997 ·UCL Discovery (University College London) ·(unknown), Dona Alberti, (unknown), Annie M. Racine, (unknown), E Alexander, Christopher Adams, John B. Porter	1
13	Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. 1997 ·Journal of Clinical Oncology ·Jordan Berlin, K D Tutsch, Paul R. Hutson, James F. Cleary, Randall Rago, R Z Arzoomanian, Dona Alberti, Chris Feierabend, George Wilding	44
14	Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients. 1997 ·Journal of Clinical Oncology ·H. Ian Robins, Daniel A. Rushing, (unknown), K D Tutsch, (unknown), Diane Β. Paul, David R. Spriggs, Carlye Kraemer, (unknown), (unknown), R Z Arzoomanian, (unknown), Dona Alberti, F d'Oleire, Rui Qu, Gregory E. Wilding, James A. Stewart	74
15	Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients. 1993 ·Journal of Clinical Oncology ·H. Ian Robins, Justin Cohen, Carol L. Schmitt, K D Tutsch, Chris Feierabend, R Z Arzoomanian, Dona Alberti, F d'Oleire, Walter Longo, (unknown)	46
16	A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions 1992 ·Cancer Chemotherapy and Pharmacology ·Howard H. Bailey, George Wilding, Kendra D. Tutsch, Rhoda Arzoomanian, Dona Alberti, Mary Beth Tombes, Jean L. Grem, David R. Spriggs	2
17	Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor 1992 ·Cancer ·Joan H. Schiller, Patricia L. Witt, (unknown), Dona Alberti, Mary Beth Tombes, Rhoda Arzoomanian, Raymond R. Brown, Richard A. Proctor, Stephan D. Voss, David R. Spriggs, Donald L. Trump, Ernest C. Borden	18
18	Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. 1991 ·PubMed ·Howard H. Bailey, K D Tutsch, R Z Arzoomanian, Mary Beth Tombes, Dona Alberti, (unknown), (unknown)	9
19	Endoluminar Sclerotherapy (ES) of Oesophageal Varices: Technique and Preliminary Results¹ 1988 ·European Journal of Pediatric Surgery ·Antonio Dessanti, Diego Falchetti, Dona Alberti, W. Rigamonti, (unknown)	1
20	Phase I study of combination therapy with platinum analogues: Cis-platin (CDDP) and carboplatin (CBDCA) 1985 ·Proceedings of the American Association for Cancer Research ·D L Trump, Jim M. Koeller, Dona Alberti	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact